ダウンロード数: 318
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
66_9_289.pdf | 598.43 kB | Adobe PDF | 見る/開く |
タイトル: | デュタステリドとα1遮断薬併用療法中のLUTS/BPH患者におけるα1遮断薬中止後の臨床経過 |
その他のタイトル: | The Clinical Course of α1 Blocker Discontinuation in Patients with LUTS/BPH Receiving Combination Therapy of Dutasteride and α1 Blocker |
著者: | 渡邊, 成樹 和田, 直樹 北, 雅史 堀, 淳一 玉木, 岳 柿崎, 秀宏 |
著者名の別形: | Watanabe, Masaki Wada, Naoki Kita, Masafumi Hori, Junichi Tamaki, Gaku Kakizaki, Hidehiro |
キーワード: | Benign prostatic hyperplasi α1 blocker discontinuation |
発行日: | 30-Sep-2020 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 66 |
号: | 9 |
開始ページ: | 289 |
終了ページ: | 292 |
抄録: | We retrospectively investigated the clinical course of α1 blocker discontinuation in patients who had lower urinary tract symptoms with benign prostate hypertrophy (LUTS/BPH) and received combination therapy ofdutasteride and α1 blocker. Among the patients with LUTS/BPH who had been receiving combination therapy, those who wished to reduce the number ofprescribed drugs and discontinue the use of α1 blocker because ofsymptom improvement were recruited in this study. Symptom scores including International Prostate Symptom Score (IPSS) and overactive bladder symptom score (OABSS), parameters ofuroflowmetry and prostate volume (PV) were evaluated at the time of α 1 blocker discontinuation. Twenty-two patients discontinued the use of α 1 blocker. The mean PV at the time of α 1 blocker discontinuation was 43.2 ml, and the mean duration ofcombination therapy was 39.4 months. In 11 (50%) patients, dutasteride monotherapy without α1 blocker was maintained for a mean follow-up of 10.5 months (9-12 months) after α1 blocker discontinuation (Non-resumption group). In the other 11 patients (50%), α1 blocker was resumed because ofthe patient's request to resume the use of α1 blocker (Resumption group). The mean length ofdutasteride monotherapy was 4. 5 months (1-8 months) in the resumption group. Compared with the non-resumption group, IPSS total score and storage sub-score ofIPSS at the time of α1 blocker discontinuation were significantly higher in the resumption group. Based on the ROC curve, IPSS total score <16, IPSS voiding/storage symptom score <7, OABSS <7 and PV 54 ml or more at the time of α1 blocker discontinuation were predictors ofnon-resumption of α1 blocker. These results suggest that if LUTS is controlled by a long-term combination therapy ofdutasteride and α1 blocker and still PV is large enough, α1 blocker can be discontinued. |
著作権等: | 許諾条件により本文は2021/10/01に公開 |
DOI: | 10.14989/ActaUrolJap_66_9_289 |
URI: | http://hdl.handle.net/2433/255209 |
PubMed ID: | 32993272 |
出現コレクション: | Vol.66 No.9 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。